The DOI matches its Crossref record; 270 of the 270 references it cites were found in a registry or an index.
Current trends in drug metabolism and pharmacokinetics
Open accessAbstract
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug-drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–270 of 270
Niu, Y., Xu, M., Slagle, B. L., Huang, H., Li, S., Guo, G. L., Shi, G., Qin, W., & Xie, W. (2016) · Hepatology · doi:10.1002/hep.28924 · Cited by 36
Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics
Riviere, J. E., Gabrielsson, J., Fink, M., & Mochel, J. P. (2015) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12278 · Cited by 35
Yu, A., Ingelman‐Sundberg, M., Cherrington, N. J., Aleksunes, L. M., Zanger, U. M., Xie, W., Jeong, H., Morgan, E. T., Turnbaugh, P. J., Klaassen, C. D., et al. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.12.006 · Cited by 35
Self-citationDecreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes
Xu, D., Li, F., Zhang, M., Zhang, J., Liu, C., Hu, M., Zhong, Z., Jia, L.-L., Wang, D., Wu, J., et al. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.39 · Cited by 34
Liu, H., Liu, L., Li, J., Mei, D., Duan, R., Hu, N., Guo, H., Zhong, Z., & Liu, X. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043513 · Cited by 34
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
Xie, C., Gao, X., Sun, D., Zhang, Y.-B., Krausz, K. W., Qin, X., & Gonzalez, F. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079723 · Cited by 34
Müller, F., Weitz, D., Mertsch, K., König, J., & Fromm, M. F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00416 · Cited by 34
Kalthoff, S., Winkler, A., Freiberg, N., Manns, M. P., & Strassburg, C. P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.028 · Cited by 33
Lee, S., & Lee, S. (2005) · Shock · doi:10.1097/01.shk.0000150778.39484.54 · Cited by 33
Wassenaar, C. A., Conti, D. V., Das, S., Chen, P., Cook, E. H., Ratain, M. J., Benowitz, N. L., & Tyndale, R. F. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0804 · Cited by 32
Papageorgiou, I. S., & Court, M. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.09.013 · Cited by 32
Zhou, M., Maitra, S. R., & Wang, P. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.4.423 · Cited by 31
OAT1 and OAT3: Targets of drug–drug interaction between entecavir and JBP485
Xu, Q., Wang, C., Meng, Q., Liu, Q., Sun, H., Peng, J., Ma, X., Kaku, T., & Liu, K. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.024 · Cited by 31
Self-citationGufford, B. T., Barr, J., González‐Pérez, V., Layton, M. E., White, J. R., Oberlies, N. H., & Paine, M. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12047 · Cited by 31
Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3
Ye, J., Liu, Q., Wang, C., et al. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.004 · Cited by 30
Feng, S., Shi, J., Parrott, N. J., Hu, P., Weber, C., Martin‐Facklam, M., Saito, T., & Peck, R. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0356-1 · Cited by 30
Jian, C., Tu, M., Ho, P. Y., Duan, Z., Zhang, Q., Qiu, J.-X., White, R. D., Wun, T., Lara, P. N., Lam, K. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16372 · Cited by 30
Self-citationGeneration and Characterization of a CYP2C11-Null Rat Model by Using the CRISPR/Cas9 Method
Wei, Y., Yang, L. C., Zhang, X., Sui, D., Wang, C.-S., Wang, K., Shan, M., Guo, D., & Wang, H. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078444 · Cited by 29
Liu, Y.-C., Liu, H., Yang, H., Wen, T., Shang, Y., Liu, X., Xie, L. Y., & Wang, G. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.021 · Cited by 28
Johnson, P., Loganathan, C., Iruthayaraj, A., Kumaradhas, P., & Palvannan, T. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.015 · Cited by 27
Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
Liang, C., Zhao, J., Lu, J., Zhang, Y., Ma, X., Shang, X., Li, Y., Ma, X., Liu, M., & Wang, X. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084277 · Cited by 27
Self-citation[Multi-compound pharmacokinetic research on Chinese herbal medicines: approach and methodology].
Li, C. (2017) · PubMed · doi:10.19540/j.cnki.cjcmm.2017.0016 · Cited by 27
Savage, R. E., Tyler, A. N., Miao, X., & Chan, T. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018655 · Cited by 26
von Richter, O., Massimini, G., Scheible, H., Udvaros, I., & Johne, A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13078 · Cited by 26
Qin, X., Lu, J., Wang, P., Xu, P., Liu, M., & Wang, X. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.013 · Cited by 26
Self-citationFarnesoid X receptor regulates SULT1E1 expression through inhibition of PGC1α binding to HNF4α
Wang, S., Yuan, X., Lu, D., Guo, L., & Wu, B. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.023 · Cited by 26
Karibe, T., Imaoka, T., Abe, K., & Ando, O. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078931 · Cited by 26
p53‐mediated regulation of bile acid disposition attenuates cholic acid‐induced cholestasis in mice
Chen, P., Li, D., Chen, Y., Sun, J., Fu, K., Guan, L., Zhang, H., Jiang, Y., Li, X., Zeng, X., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14035 · Cited by 25
Self-citationSatoh, D., Abe, S., Kobayashi, K., Nakajima, Y., Oshimura, M., & Kazuki, Y. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.01.002 · Cited by 25
The role of hepatic cytochrome P-450 in sepsis.
Jacob, A., Zhou, M., Wu, R., & Wang, P. (2009) · PubMed · Cited by 24
Jiang, M., & Xie, W. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.743561 · Cited by 24
Intestinal Azo-reduction and Glucuronide Conjugation of Prontosil
Gingell, R., & Bridges, J. W. (1973) · Xenobiotica · doi:10.3109/00498257309151548 · Cited by 24
Bioengineered non-coding RNA agent (BERA) in action
Duan, Z., & Yu, A. (2016) · Bioengineered · doi:10.1080/21655979.2016.1207011 · Cited by 24
Self-citationZhao, H., Li, S., Yang, Z., Peng, Y., Chen, X., & Zheng, J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079327 · Cited by 24
Self-citationLi, G., Zheng, Q., Yu, Y., Zhong, W., Zhou, H., Qiu, F., Wang, G., Yu, G., & Derendorf, H. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00737-5 · Cited by 24
Degradation of DOPA by Intestinal Microorganisms in Vitro
Bakke, O. M. (1971) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1971.tb00640.x · Cited by 22
Wang, F., Miao, M., Sun, B., Wang, Z., Tang, X., Chen, Y., Zhao, K., Liu, X., & Liu, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.54 · Cited by 22
Cheng, X., Liu, F., Liu, H., Wang, G., & Hao, H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.160 · Cited by 22
Hou, X., Zhou, J., Yu, S., Zhou, L., Zhang, Y., Zhong, D., & Chen, X. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081182 · Cited by 22
Self-citationShu, N., Hu, M., Liu, C., Zhang, M., Ling, Z., Zhang, J., Xu, P., Zhong, Z., Yang, C., Liu, L., et al. (2016) · Xenobiotica · doi:10.3109/00498254.2016.1141437 · Cited by 21
Yi, M., Shin, J., & Lee, S. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.07.009 · Cited by 21
Sukkummee, W., Jittisak, P., Wonganan, P., Wittayalertpanya, S., Chariyavilaskul, P., & Leelahavanichkul, A. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1602054 · Cited by 21
Glutathione S-transferase A1 (GSTA1) as a marker of acetaminophen-induced hepatocyte injury in vitro
Li, R., Liu, F., Chang, Y., Ma, X., Li, M., Li, C., Shi, C., He, J., Li, Y., Li, Z., et al. (2017) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2017.1320457 · Cited by 20
Self-citationLiu, L., Miao, M., Chen, Y., Wang, Z., Sun, B., & Liu, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00190 · Cited by 20
Yim, D., Kim, M. J., Shin, Y., Lee, S., Shin, J., & Kim, D. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2673769 · Cited by 20
Nozaki, K., Nakano, M., Iwakami, C., Fukami, T., & Nakajima, M. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086702 · Cited by 20
Hsueh, C., Hsu, V., Pan, Y., & Zhao, P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0635-8 · Cited by 19
Xu, M., Hao, H., Jiang, L., Long, F., Wei, Y., Ji, H., Sun, B., Peng, Y. H., Wang, G., Ju, W., et al. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.02.001 · Cited by 18
Liu, D., Song, H., Song, L., Liu, Y., Cao, Y., Jiang, J., & Hu, P. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1205761 · Cited by 18
Self-citationAlegre, F., Ormonde, A. R., Snider, K. M., Woolard, K., Yu, A., & Wittenburg, L. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209941 · Cited by 18
Self-citationZhang, R., Yang, X., Li, J., Wu, J., Peng, W.-X., Dong, X., Zhou, S., & Yu, X. (2008) · American Journal of Nephrology · doi:10.1159/000129073 · Cited by 17
Guo, X., Meng, Q., Liu, Q., Wang, C., Mao, Q., Sun, H., Peng, J., Kaku, T., & Liu, K. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-089 · Cited by 17
Self-citationDysregulations of Intestinal and Colonic UDP-glucuronosyltransferases in Rats with Type 2 Diabetes
Xie, H., Sun, S., Cheng, X., Yan, T., Zheng, X., Li, F., Qi, Q., Wang, G., & Hao, H. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-020 · Cited by 17
Extract of Rhus verniciflua stokes protects the diet-induced hyperlipidemia in mice
Jeong, S., Park, J., Kim, S., Kweon, H. Y., Seo, S., Na, D. S., Lee, D., Hong, C. Y., Na, C.-S., Dong, M., et al. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0579-6 · Cited by 17
Regulation of drug-metabolizing enzymes by local and systemic liver injuries
Guo, Y., Hu, B., Xie, Y., Billiar, T. R., Sperry, J. L., Huang, M., & Xie, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1139574 · Cited by 16
Covalent Thiol Adducts Arising from Reactive Intermediates of Cocaine Biotransformation
Schneider, K. J., & DeCaprio, A. P. (2013) · Chemical Research in Toxicology · doi:10.1021/tx4003116 · Cited by 16
Liu, D., Ma, X., Liu, Y., Zhou, H., Shi, C., Wu, F. S.-Y., Jiang, J., & Hu, P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.020 · Cited by 16
Self-citationActivation of Liver X Receptor Attenuates Oleic Acid–Induced Acute Respiratory Distress Syndrome
Zhao, Z., Xu, D., Li, S., He, B., Huang, Y., Xu, M., Ren, S., Li, S., Wang, H., & Xie, W. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.06.018 · Cited by 16
Yi, M., Cho, S., Min, J., Kim, D., Shin, J., & Lee, S. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.03.010 · Cited by 16
Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin
Yang, B., Gillespie, B., Smith, B. P., Smith, W. B., Lissmats, A., Rudebeck, M., Kullenberg, T., & Olsson, B. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.516 · Cited by 15
Matsson, E. M., Eriksson, U. G., Palm, J. E., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400341t · Cited by 15
Notenboom, S., Weigand, K. M., Proost, J. H., van Lipzig, M. M. H., van de Steeg, E., van den Broek, P. H. H., Greupink, R., Rüssel, F. G. M., & Groothuis, G. M. M. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.01.007 · Cited by 15
Yang, C., Zhao, K., Liu, F., Li, Y., Zhong, Z., Hong, S., Liu, X., & Liu, L. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079830 · Cited by 15
Self-citationEffects of catalpol on the activity of human liver cytochrome P450 enzymes
Liu, L., Cao, X., Li, T., & Li, X. (2018) · Xenobiotica · doi:10.1080/00498254.2018.1558309 · Cited by 14
Liu, H., Chen, M., Yin, H., Hu, P., Wang, Y., Liu, F., Tian, X., & Huang, C. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.03.044 · Cited by 13
Song, L., Zhang, Y., Jiang, J., Ren, S., Chen, L., Liu, D.-Y., Chen, X.-J., & Hu, P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0631-z · Cited by 12
Self-citationCannady, E. A., Suico, J. G., Wang, M., Friedrich, S. W., Rehmel, J., Nicholls, S. J., & Krueger, K. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12730 · Cited by 11
Gao, R., Liu, M., Chen, Y., Xia, C., Zhang, H., Xiong, Y., & Huang, S. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.11.010 · Cited by 10
Wang, C., Huo, X., Wang, C., Meng, Q., Liu, Z., Sun, P., Cang, J., Sun, H., & Liu, K. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.05.011 · Cited by 5
Self-citationHwang, D.-K., Kim, J., Shin, Y., Choi, W.-G., Kim, S., Cho, Y., Lee, J. Y., Kang, H. C., & Lee, H. S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070355 · Cited by 5
Cited by
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,061
The Bioavailability of Drugs—The Current State of Knowledge
Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, A. (2023) · Molecules · doi:10.3390/molecules28248038 · Cited by 391
The Promise of Nanotechnology in Personalized Medicine
Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 284
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Biological sex differences in pharmacokinetics and adverse drug reactions
Aljohmani, A., & Yildiz, D. (2026) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04721-8 · Cited by 35
Metadata
- Authors
- Li, Y., Meng, Q., Yang, M., Liu, D., Hou, X., Tang, L., Wang, X., Lyu, Y., Chen, X., Liu, K., Yu, A.-M., Zuo, Z., & Bi, H.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 9
- Issue
- 6
- Pages
- 1113-1144
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W2981132553
- Cited by
- 391
- References
- 270
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.